Neuroprotective Effect of σ 1 -Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal Nitric Oxide Production
- 1 July 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (7) , 1613-1620
- https://doi.org/10.1161/01.str.32.7.1613
Abstract
Background and Purpose—The potent σ1-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) provides neuroprotection in experimental stroke. We tested the hypothesis that PPBP attenuates striatal tissue damage after middle cerebral artery occlusion (MCAO) by a mechanism involving reduction of ischemia-evoked nitric oxide (NO) production. Furthermore, we determined whether the agent fails to protect ischemic brain when neuronal nitric oxide synthase (nNOS) is genetically deleted or pharmacologically inhibited (selective nNOS inhibitor, 7-nitroindazole [7-NI]). Methods—Halothane-anesthetized adult male Wistar rats were subjected to 2 hours of MCAO by the intraluminal filament occlusion technique. All physiological variables were controlled during the ischemic insult. In vivo striatal NO production was estimated via microdialysis by quantification of local, labeled citrulline recovery after labeled arginine infusion. In a second series of experiments, nNOS null mutants (nNOSKOs) and the genetically matched wild-type (WT) strain were treated with 90 minutes of MCAO. Brains were harvested at 22 hours of reperfusion for measurement of infarction volume by triphenyltetrazolium chloride histology. Results—PPBP attenuated infarction volume at 22 hours of reperfusion in cerebral cortex and striatum and markedly attenuated NO production in ischemic and nonischemic striatum during occlusion and early reperfusion. Treatment with 7-NI mimicked the effects of PPBP. In WT mice, infarction volume was robustly decreased by both PPBP and 7-NI, but the efficacy of PPBP was not altered by pharmacological nNOS inhibition in combined therapy. In contrast, PPBP did not decrease infarction volume in nNOSKO mice. Conclusions—These data suggest that the mechanism of neuroprotection of PPBP in vivo is through attenuation of nNOS activity and ischemia-evoked NO production. Neuroprotective effects of PPBP are lost when nNOS is not present or is inhibited; therefore, PPBP likely acts upstream from NO generation and its subsequent neurotoxicity.Keywords
This publication has 27 references indexed in Scilit:
- Estrogen Receptor Antagonist ICI182,780 Exacerbates Ischemic Injury in Female MouseJournal of Cerebral Blood Flow & Metabolism, 2000
- Neuroprotection from Focal Ischemia by 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Dependent on Treatment Duration in RatsAnesthesia & Analgesia, 1998
- Characterization of Metabotropic Glutamate Receptor-Mediated Nitric Oxide Production in VivoJournal of Cerebral Blood Flow & Metabolism, 1997
- ARL 17477, a Potent and Selective Neuronal NOS Inhibitor Decreases Infarct Volume after Transient Middle Cerebral Artery Occlusion in RatsJournal of Cerebral Blood Flow & Metabolism, 1996
- Neuroprotective sigma ligands interfere with the glutamate‐activated NOS pathway in hippocampal cell cultureSynapse, 1995
- Inducible Nitric Oxide Synthase Gene Expression in Brain following Cerebral IschemiaJournal of Cerebral Blood Flow & Metabolism, 1995
- In vivo labeling of sigma receptors in mouse brain with [3H]4‐phenyl‐1‐(4‐phenylbutyl)piperidineSynapse, 1995
- Excitatory Amino Acid‐Mediated Cytotoxicity and Calcium Homeostasis in Cultured NeuronsJournal of Neurochemistry, 1993
- BMY-14802 protects against ischemia-induced neuronal damage in the gerbilLife Sciences, 1992
- Localization of nitric oxide synthase indicating a neural role for nitric oxideNature, 1990